Arrhythmia Management

Diagnostic Evaluation

• Patients with symptoms of severe dyspnea during palpitations should undergo evaluation, as they may be at risk for hemodynamic compromise, according to the American College of Cardiology 1
• A 12-lead ECG is essential for documenting the arrhythmia pattern and evaluating the QT interval, particularly in patients with sustained arrhythmia, as recommended by the American College of Cardiology 1
• Echocardiography is recommended to exclude structural heart disease, especially in patients with sustained arrhythmias, according to the American College of Cardiology 1
• Ambulatory monitoring, such as 24-hour Holter monitoring or event recorders, may be used to diagnose arrhythmias in patients with frequent episodes, as suggested by the American College of Cardiology 1
• A 12-lead ECG should be performed to evaluate QT interval and assess for other abnormalities, and an echocardiogram should be done to determine ventricular function and structural abnormalities, as recommended by the European Society of Cardiology 2
• 24-hour Holter monitoring should be considered for complex ventricular arrhythmias, as suggested by the European Society of Cardiology 2

Patient Selection for Treatment

• Patients with severe symptoms during palpitations, such as syncope or dyspnea, should be considered for treatment, as they may be at risk for hemodynamic instability, according to the American College of Cardiology 1
• Patients with bigeminy/trigeminy associated with structural heart disease may be considered for treatment, as recommended by the American College of Cardiology 1
• The following risk categories have been defined:

Treatment and Management

• Beta-blockers are recommended as the first-line treatment for symptomatic ventricular bigeminy in patients with structurally normal hearts, followed by non-dihydropyridine calcium channel blockers if beta-blockers are ineffective or not tolerated, according to the American College of Cardiology 3
• Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, are recommended as second-line treatment if beta-blockers are ineffective or contraindicated, as noted by the American College of Cardiology 3
• The European Heart Journal advises against the use of dihydropyridine calcium channel blockers, such as nifedipine, as they may worsen symptoms 4
• Antiarrhythmic therapy with sodium channel blockers (Class IC agents) may be considered for symptomatic patients, as suggested by the European Heart Journal 5
• For hemodynamically unstable patients, supportive care, CPR if necessary, and reassessment after 2 minutes are recommended, according to the American Heart Association 6
• For bigeminy associated with long QT syndrome, withdrawal of QT-prolonging drugs, correction of electrolyte abnormalities, and magnesium sulfate infusion are recommended, as noted by the European Heart Journal 7
• For bigeminy associated with structural heart disease, consultation with a pediatric cardiologist/electrophysiologist and consideration of ICD therapy for high-risk patients are recommended, according to the American College of Cardiology 8, 9
• Low-risk patients can be reassured, avoid triggers (caffeine, alcohol, stress), and do not require specific antiarrhythmic therapy, with follow-up ECG in 1 month if frequent, as recommended by the American College of Cardiology 3, 10, 2

Prognosis and Complications

• In patients with structurally normal hearts, ventricular bigeminy generally has a benign prognosis, although the strength of evidence is not specified, as noted by the European Society of Cardiology 2
• In patients with underlying cardiac disease, especially coronary artery disease or cardiomyopathy, ventricular bigeminy may be associated with increased mortality risk, according to the European Society of Cardiology 2
• Ventricular bigeminy can be a manifestation of serious underlying disorders such as continuing ischemia, pump failure, altered autonomic tone, hypoxia, or electrolyte disturbances that require attention and corrective measures, as noted by the European Heart Society 11
• Hypertrophic cardiomyopathy, dilated cardiomyopathy, electrolyte abnormalities, thyroid dysfunction, pheochromocytoma, primary aldosteronism, and myocardial ischemia can cause bigeminy, according to the American College of Cardiology 12 and the American Heart Association 13, 9
• Correction of electrolyte abnormalities, such as maintaining potassium levels >4.5 mmol/L, and avoidance of medications that prolong the QT interval are recommended, as noted by the European Society of Cardiology 2 and the American Heart Association 14